Loader

Pathways

PathWhiz ID Pathway Meta Data

PW144900

Pw144900 View Pathway
drug action

Haloprogin Drug Metabolism Action Pathway

Homo sapiens

PW176063

Pw176063 View Pathway
metabolic

Haloprogin Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Haloprogin are predicted with biotransformer.

PW145247

Pw145247 View Pathway
drug action

Halothane Drug Metabolism Action Pathway

Homo sapiens

PW127743

Pw127743 View Pathway
drug action

Halothane GABA(A) Anesthetic Action Pathway

Homo sapiens
Halothane is a general inhalation anesthetic used for the induction and maintenance of general anesthesia. A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. Halothane causes general anaethesia due to its actions on multiple ion channels, which ultimately depresses nerve conduction, breathing, cardiac contractility. Its immobilizing effects have been attributed to its binding to potassium channels in cholinergic neurons. Halothane's effect are also likely due to binding to NMDA and calcium channels, causing hyperpolarization. It can be found under the brand name Fluothane and the exact mechanism of the action of general anaesthetics has not been delineated. Halothane activates GABAA and glycine receptors. It also acts as an NMDA receptor antagonist, inhibits nACh and voltage-gated sodium channels, and activates 5-HT3 and twin-pore K+ channels. Its action stems from binding to the GABA(A) receptor to depress nerve conduction. Some side effects of using halothane may include cardiorespiratory instability, mild liver dysfunction, and kidney damage.

PW128065

Pw128065 View Pathway
drug action

Halothane NMDA Antagonist Action Pathway

Homo sapiens
Halothone is a general inhalation anesthetic used for the induction and maintenance of general anaesthesia. It provides relatively rapid infuction with little or no excitement. Halothane may not produce sufficient muscle relaxation, so supplemental neuromuscular blocking agents may be required as well. Halothone is diffused across the blood-brain barrier after being inhaled. It then antagonizes NMDA receptors in the brain. This prevents glutamate from binding to NMDA receptors as readily. This prevents calcium from entering the postsynaptic neuron which leads to hyperpolarization. This hyperpolarization of neurons causes an anaesthetic effect.

PW146383

Pw146383 View Pathway
drug action

Hard fat Drug Metabolism Action Pathway

Homo sapiens

PW000218

Pw000218 View Pathway
disease

Hartnup Disorder

Homo sapiens
Hartunup Disorder (HND, Hartnup Disease) is an autosomal recessive disease caused by a mutation in the SLC6A19 which codes for sodium-dependent neutral amino acid transporter B(0). A deficiency in this enzyme results in accumulation of L-alanine, L-asparagine, L-histidine, indoleacetic acid, L-isoleucine, L-leucine, L-phenylalanine, L-serine, L-threonine, L-tryptophan, L-valine, and L-tyrosine in urine. Symptoms include pellagra, psychosis, ataxia, and mental retardation. Treatment includes nicotinamide.

PW122027

Pw122027 View Pathway
disease

Hartnup Disorder

Rattus norvegicus
Hartunup Disorder (HND, Hartnup Disease) is an autosomal recessive disease caused by a mutation in the SLC6A19 which codes for sodium-dependent neutral amino acid transporter B(0). A deficiency in this enzyme results in accumulation of L-alanine, L-asparagine, L-histidine, indoleacetic acid, L-isoleucine, L-leucine, L-phenylalanine, L-serine, L-threonine, L-tryptophan, L-valine, and L-tyrosine in urine. Symptoms include pellagra, psychosis, ataxia, and mental retardation. Treatment includes nicotinamide.

PW121802

Pw121802 View Pathway
disease

Hartnup Disorder

Mus musculus
Hartunup Disorder (HND, Hartnup Disease) is an autosomal recessive disease caused by a mutation in the SLC6A19 which codes for sodium-dependent neutral amino acid transporter B(0). A deficiency in this enzyme results in accumulation of L-alanine, L-asparagine, L-histidine, indoleacetic acid, L-isoleucine, L-leucine, L-phenylalanine, L-serine, L-threonine, L-tryptophan, L-valine, and L-tyrosine in urine. Symptoms include pellagra, psychosis, ataxia, and mental retardation. Treatment includes nicotinamide.

PW000181

Pw000181 View Pathway
disease

Hawkinsinuria

Homo sapiens
Hawkinsinuria (4-Hydroxyphenylpyruvate Hydroxylase Deficiency) is an autosomal dominant disease caused by a mutation in the HPD gene which codes for 4-hydroxyphenylpyruvate dioxygenase. A deficiency in this enzyme results in accumulation of hawkinsin in urine and plasma; cis-4-hydroxycyclohexylacetic acid, trans-4-hydroxycyclohexylaceid, vanillactic acid, 4-hydroxyphenylpyruvic acid, pyroglutamic acid in urine; and L-tyrosine in plasma. Symptoms include ketosis, metabolic acidosis, swimming-pool odor, and mental retardation. Treatment includes a low-protein diet and vitamin C.